Lung cancer can be hereditary, with mutations in the EGFR and KRAS genes potentially playing a role. Smoking, however, is by far the biggest risk factor.

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

Lung cancer may be curable, depending on a number of factors, including your age, health, stage of cancer, and how it ...

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

Nearly a quarter of all newly diagnosed patients with advanced lung cancer are not given a test that could improve their chances for long-term survival and reduce their side effects.

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central ...

With EAGLE, lung cancer biopsy analysis is expedited, accurately predicting EGFR mutations and streamlining the diagnostic process for better patient outcomes.

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

About ZEGFROVY® (sunvozertinib) ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity.

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Efficacy was evaluated in WU-KONG1B, a multinational, open-label, dose-randomization trial. Patients enrolled had locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 ...